Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.
Formation and development of a thrombus or blood clot in the blood vessel.
The veins and arteries of the HEART.
Radiography of the vascular system of the heart muscle after injection of a contrast medium.
The formation or presence of a blood clot (THROMBUS) within a vein.
The circulation of blood through the CORONARY VESSELS of the HEART.
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.
A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
Dibenzothiepins are a class of tricyclic heterocyclic compounds sharing a common structure of two benzene rings fused to a thiepin ring, which have been used in the development of various pharmaceutical drugs, particularly as antipsychotic agents, but are not widely used in current clinical practice due to their adverse effects profile.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
Narrowing or constriction of a coronary artery.
An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5.
Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Formation or presence of a blood clot (THROMBUS) in the CRANIAL SINUSES, large endothelium-lined venous channels situated within the SKULL. Intracranial sinuses, also called cranial venous sinuses, include the superior sagittal, cavernous, lateral, petrous sinuses, and many others. Cranial sinus thrombosis can lead to severe HEADACHE; SEIZURE; and other neurological defects.
Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Spasm of the large- or medium-sized coronary arteries.
Formation or presence of a blood clot (THROMBUS) in a blood vessel within the SKULL. Intracranial thrombosis can lead to thrombotic occlusions and BRAIN INFARCTION. The majority of the thrombotic occlusions are associated with ATHEROSCLEROSIS.
Elements of limited time intervals, contributing to particular results or situations.
Disease having a short and relatively severe course.
Blood clot formation in any part of the CAROTID ARTERIES. This may produce CAROTID STENOSIS or occlusion of the vessel, leading to TRANSIENT ISCHEMIC ATTACK; CEREBRAL INFARCTION; or AMAUROSIS FUGAX.
Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Devices that provide support for tubular structures that are being anastomosed or for body cavities during skin grafting.
A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting.
Agents that prevent clotting.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Radiographic visualization or recording of a vein after the injection of contrast medium.
Formation or presence of a blood clot (THROMBUS) in the SUPERIOR SAGITTAL SINUS or the inferior sagittal sinus. Sagittal sinus thrombosis can result from infections, hematological disorders, CRANIOCEREBRAL TRAUMA; and NEUROSURGICAL PROCEDURES. Clinical features are primarily related to the increased intracranial pressure causing HEADACHE; NAUSEA; and VOMITING. Severe cases can evolve to SEIZURES or COMA.
The hospital unit in which patients with acute cardiac disorders receive intensive care.
Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures.
The use of ultrasound to guide minimally invasive surgical procedures such as needle ASPIRATION BIOPSY; DRAINAGE; etc. Its widest application is intravascular ultrasound imaging but it is useful also in urology and intra-abdominal conditions.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The vein accompanying the femoral artery in the same sheath; it is a continuation of the popliteal vein and becomes the external iliac vein.
A vein on either side of the body which is formed by the union of the external and internal iliac veins and passes upward to join with its fellow of the opposite side to form the inferior vena cava.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
DEEP VEIN THROMBOSIS of an upper extremity vein (e.g., AXILLARY VEIN; SUBCLAVIAN VEIN; and JUGULAR VEINS). It is associated with mechanical factors (Upper Extremity Deep Vein Thrombosis, Primary) secondary to other anatomic factors (Upper Extremity Deep Vein Thrombosis, Secondary). Symptoms may include sudden onset of pain, warmth, redness, blueness, and swelling in the arm.
Pathologic deposition of calcium salts in tissues.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
The restoration of blood supply to the myocardium. (From Dorland, 28th ed)
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
The return of a sign, symptom, or disease after a remission.
Bleeding or escape of blood from a vessel.
Surgical removal of an obstructing clot or foreign material from a blood vessel at the point of its formation. Removal of a clot arising from a distant site is called EMBOLECTOMY.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
Coronary artery bypass surgery on a beating HEART without a CARDIOPULMONARY BYPASS (diverting the flow of blood from the heart and lungs through an oxygenator).
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Veins draining the cerebrum.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
Drugs used to cause dilation of the blood vessels.
Obstruction of flow in biological or prosthetic vascular grafts.
A value equal to the total volume flow divided by the cross-sectional area of the vascular bed.
Formation or presence of a blood clot (THROMBUS) in the CAVERNOUS SINUS of the brain. Infections of the paranasal sinuses and adjacent structures, CRANIOCEREBRAL TRAUMA, and THROMBOPHILIA are associated conditions. Clinical manifestations include dysfunction of cranial nerves III, IV, V, and VI, marked periorbital swelling, chemosis, fever, and visual loss. (From Adams et al., Principles of Neurology, 6th ed, p711)
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The venous trunk which receives blood from the lower extremities and from the pelvic and abdominal organs.
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
The hollow, muscular organ that maintains the circulation of the blood.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Maintenance of blood flow to an organ despite obstruction of a principal vessel. Blood flow is maintained through small vessels.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
Formation or presence of a blood clot (THROMBUS) in the LATERAL SINUSES. This condition is often associated with ear infections (OTITIS MEDIA or MASTOIDITIS) without antibiotic treatment. In developed nations, lateral sinus thrombosis can result from CRANIOCEREBRAL TRAUMA; BRAIN NEOPLASMS; NEUROSURGICAL PROCEDURES; THROMBOPHILIA; and other conditions. Clinical features include HEADACHE; VERTIGO; and increased intracranial pressure.
A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.
Pressure, burning, or numbness in the chest.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
The degree to which BLOOD VESSELS are not blocked or obstructed.

Intravenous magnesium reduces infarct size after ischemia/reperfusion injury combined with a thrombogenic lesion in the left anterior descending artery. (1/1009)

Experimental studies have demonstrated that intravenous magnesium (Mg) can protect the ischemic myocardium and has an antithrombotic effect. In patients with myocardial infarction, the reperfusion injury is complicated by the presence of a thrombogenic area in the affected coronary artery that may cause repetitive thrombus formation and embolization. We investigated the effect of Mg on infarct size in a randomized study in pigs. Myocardial infarction was induced by a 50-minute mechanical occlusion of the left anterior descending artery combined with an arterial injury, which stimulated a dynamic thrombus formation with emboli shedding on reperfusion. Magnesium sulfate (6 mmol/20 min plus 3 mmol/h) or saline was started at 30 minutes after coronary occlusion. Real-time ventricular pressure-volume loops were generated from the left ventricle by using a microtip pressure manometer and a conductance catheter. Platelet accumulation in the myocardium was evaluated by using 111In-labeled platelets. After 4 hours of reperfusion, the infarct size/area at risk ratio in the placebo group was 46+/-0.06% (n=8) compared with 22+/-0.07% (n=6) in the Mg-treated animals (P=0. 03). Ejection fraction decreased significantly in the control group but not in the Mg-treated animals (P=0.03). Platelet accumulation in the myocardium did not change significantly between the Mg- and placebo-treated animals (placebo group, 191+/-19%; Mg group, 177+/-29%; NS). The present study demonstrates that intravenous Mg infusion is able to reduce infarct size by >50% and preserve the ejection fraction in this model where ischemia/reperfusion injury was evaluated in the presence of a thrombogenic area in the nutrient artery.  (+info)

A role for changes in platelet production in the cause of acute coronary syndromes. (2/1009)

Platelets are heterogeneous with respect to their size, density, and reactivity. Large platelets are more active hemostatically, and platelet volume has been found to be increased both in patients with unstable angina and with myocardial infarction. Furthermore, platelet volume is a predictor of a further ischemic event and death when measured after myocardial infarction. Platelets which are anucleate cells with no DNA are derived from their precursor, the megakaryocyte. Therefore, it is suggested that changes in platelet size are determined at thrombopoiesis in the megakaryocyte and that those changes might precede acute cardiac events. Understanding of the signaling system that controls platelet production may also further elucidate the cascade of events leading to acute vascular occlusion in some patients.  (+info)

Endothelial injuries of coronary arteries distal to thrombotic sites: role of adhesive interaction between endothelial P-selectin and leukocyte sialyl LewisX. (3/1009)

Intracoronary thrombus formation is associated with epicardial vasoconstriction distal to the thrombotic site. To investigate the mechanisms of abnormal vasomotor function of the artery distal to the thrombotic site, we studied coronary vessels in dogs with cyclic flow variations (CFVs) of the left anterior descending coronary artery (LAD) stenosis with endothelial injury. Coronary rings isolated from the LAD (proximal, stenotic, and distal sites) and control circumflex coronary arteries were tested for responsiveness to endothelium-dependent (acetylcholine and A23187) and endothelium-independent vasodilators (NaNO2). Endothelium-independent relaxation was intact in all 4 sites. Endothelium-dependent relaxation was intact in the control and proximal sites and impaired in the stenotic sites. Relaxations not only to acetylcholine and A23187 but also to serotonin, ADP, and thrombin were impaired in the distal sites after observing CFVs for 80 minutes. Electron microscopy revealed the loss of endothelial integrity with leukocyte adherence to the endothelium in the distal sites. Immunohistochemical expression of P-selectin on the endothelial cells was more upregulated in the distal site than in the proximal site, and P-selectin mRNA expression was significantly greater in the ischemic region distal to the thrombotic site than in the proximal nonischemic region. PB1.3, a neutralizing monoclonal antibody against P-selectin, and sialyl LewisX (SLeX)-containing oligosaccharide SLeX, a carbohydrate analogue of selectin ligand, preserved endothelial function without affecting CFVs. SLeX-containing oligosaccharide preserved endothelial integrity of the distal site and inhibited P-selectin expression of the distal site. Thus, the adhesive interaction between endothelial P-selectin and leukocyte SLeX may play an important role in endothelial injuries of the coronary artery distal to the thrombotic site.  (+info)

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. (4/1009)

The small molecule direct thrombin inhibitor L-374,087 was characterized across species in an in vitro activated partial thromboplastin clotting time (aPTT) assay and in vivo in rhesus monkey and dog thrombosis models. In vitro in rhesus, dog, and human plasma, L-374,087 concentrations eliciting 2-fold increases in aPTT were 0.25, 1.9, and 0.28 microM, respectively. In anesthetized rhesus monkeys, 300 microgram/kg bolus plus 12 microgram/kg/min and 300 microgram/kg bolus plus 30 microgram/kg/min L-374,087 i.v. infusions significantly reduced jugular vein thrombus extension, with both regimens limiting venous thrombus extension to 2-fold that of baseline thrombus mass compared with a 5-fold extension observed in the vehicle control group. Antithrombotic efficacy in the rhesus with the lower-dose regimen was achieved with 2.3- to 2.4-fold increases in aPTT and prothrombin time. In a conscious instrumented dog model of electrolytic vessel injury, the oral administration of two 10 mg/kg L-374,087 doses 12 h apart significantly reduced jugular vein thrombus mass, reduced the incidence of and delayed time to occlusive coronary artery thrombosis, and significantly reduced coronary artery thrombus mass and ensuing posterolateral myocardial infarct size. Antithrombotic efficacy in the dog was achieved with 1.6- to 2.0-fold increases in aPTT at 1 to 6 h after oral dosing with L-374,087. These results indicate significant antithrombotic efficacy against both venous and coronary arterial thrombosis with L-374,087 with only moderate elevations in aPTT or prothrombin time. The oral efficacy of L-374,087 characterizes this compound as a prototype for the further development of orally active direct thrombin inhibitors.  (+info)

Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. (5/1009)

OBJECTIVES: The objective of this prospective study was to evaluate the relation between high lipoprotein(a) levels and thrombotic and restenotic events after coronary stent implantation. BACKGROUND: Lipoprotein(a) may promote atherogenesis, coronary thrombosis and restenosis after balloon angioplasty, but the clinical significance remains unclear. METHODS: The study included 2,223 consecutive patients with successful coronary stent placement. According to the serum level of lipoprotein(a), patients were divided in two groups: 457 patients of the highest quintile formed the high lipoprotein(a) group, and 1,766 patients of the lower four quintiles formed the low lipoprotein(a) group. Primary end points were the incidence of angiographic restenosis at six months and the event-free survival at one year. Secondary end point was the incidence of angiographic stent occlusion. RESULTS: Early stent occlusion occurred in four of the 457 patients (0.9%) with high and 37 of the 1,766 patients (2.1%) with low lipoprotein(a) levels, odds ratio of 0.41 (95% confidence interval, 0.15 to 1.16). Angiographic restenosis occurred in 173 of the 523 lesions (33.2%) in the high lipoprotein(a) group and 636 of the 1,943 lesions (32.7%) in the low lipoprotein(a) group, odds ratio of 1.02 (0.83 to 1.25). The probability of event-free survival was 73.0% in the high lipoprotein(a) group and 74.8% in the low lipoprotein(a) group (p = 0.45). On the basis of the findings in the low lipoprotein(a) group, the power of this study to detect a 25% increase in the incidence of restenosis and adverse events in the group with elevated lipoprotein(a) was 90% and 75%, respectively. CONCLUSIONS: Elevated lipoprotein(a) levels did not influence the one-year clinical and angiographic outcome after stent placement. Thrombotic events and measures of restenosis were not adversely affected by the presence of high lipoprotein(a) levels.  (+info)

Antithrombin activity during the period of percutaneous coronary revascularization: relation to heparin use, thrombotic complications and restenosis. (6/1009)

OBJECTIVES: This study evaluated changes in antithrombin (AT) activity around the time of percutaneous transluminal coronary revascularization (PTCR) with unfractionated heparin anticoagulation and the effects these changes had on major thrombotic complications of PTCR. BACKGROUND: Heparin is used during PTCR to prevent thrombosis. However, heparin, a cofactor for AT, causes AT activity to fall. AT activity <70% is associated with thrombosis. There is a prothrombotic state after heparin discontinuation that has not been well explained. METHODS: Antithrombin activity was sampled at the start and end of PTCR and the next two mornings in 250 consecutive patients. We recorded occurrence of major thrombotic events, defined as 1) major thrombotic complications of PTCR; 2) major in-lab thrombus formation; or 3) subacute occlusion. Discriminant analysis was employed to evaluate the relationship of AT activity to these events. Change in AT activity and its relationship to heparin was evaluated. Evidence of restenosis at six months was obtained. RESULTS: There were 14 major thrombotic events. Antithrombin activity <70% was strongly (p = 0.006) associated with these events. The AT activity fell significantly through the morning after PTCR when 21% of patients had AT activity <70%; AT activity did not normalize until >20 h after heparin discontinuation. Pre-PTCR use of heparin led to lower AT activity in proportion to duration of heparin use. There was no relationship between AT activity and restenosis. CONCLUSIONS: Low AT activity may contribute to major thrombotic complications of PTCR. The way heparin is used before and after PTCR is important to development of low AT activity.  (+info)

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. (7/1009)

OBJECTIVES: The study sought to determine the effects of lipid-lowering with pravastatin on the systemic fibrinolytic profile and on thrombus formation under dynamic flow conditions. BACKGROUND: Lowering cholesterol (C) decreases clinical events in coronary artery disease (CAD) patients, but an analysis of the effects of lipid-lowering on the entire hemostatic and thrombotic profile has not been conducted. METHODS: We prospectively studied 93 stable patients with untreated low-density lipoprotein cholesterol (LDL-C) >145 mg/dl. The CAD patients received pravastatin, and non-CAD patients were randomized to pravastatin versus placebo (double-blind). Thrombus formation upon an injured vascular surface was assessed in a substudy of 40 patients with a previously validated ex vivo perfusion chamber system. Systemic hemostatic markers and thrombus formation were evaluated at baseline, three and six months. RESULTS: Placebo produced no changes in either the lipid profile, any of the hemostatic markers, or the ex vivo thrombus formation. Both pravastatin groups (CAD and non-CAD) showed decreased LDL-C by 30% within 6 weeks (188 to 126 mg/dl, p < 0.001 vs. baseline), and decreased plasminogen activator inhibitor-1 at 3- and 6-month follow-up compared to baseline (15% to 18% decrease at 3 months and 21% to 23% at 6 months). For the tissue plasminogen activator antigen, CAD and non-CAD groups showed significant decreases at 6 months compared to baseline (10% and 13%, respectively). No significant changes were observed with treatment in d-dimer, fibrinopeptide A, prothrombin fragment F1.2, factor VIIa, von Willebrand factor, or C-reactive protein. Fibrinogen levels were significantly increased at 6 months compared to baseline, though still below the upper normal limit. In the perfusion chamber substudy, there was a decrease in thrombus area in non-CAD patients treated with pravastatin at both 3 and 6 months compared to baseline (by 21% and 34%, respectively). The CAD patients showed decreases in thrombus formation by 13% at 3 months, and by 16% at 6 months. The change in LDL-C- correlated modestly with the change in thrombus formation (r = 0.49; p < 0.01). CONCLUSIONS: Pravastatin therapy significantly decreased thrombus formation and improved the fibrinolytic profile in patients with and without CAD. These early effects may, in part, explain the benefit rendered in primary and secondary prevention of CAD.  (+info)

Adhesive interaction between P-selectin and sialyl Lewis(x) plays an important role in recurrent coronary arterial thrombosis in dogs. (8/1009)

Cell adhesion molecules may play an important role in the disease process of acute coronary syndromes. We have shown a neutralizing anti-P-selectin monoclonal antibody and a sialyl Lewis(x)-containing oligosaccharide (SLe(x)-OS), an analogue of selectin ligand on leukocytes, reduce cyclic flow variations (CFVs) in a canine model of recurrent coronary arterial thrombosis, suggesting the important interaction between P-selectin and SLex for the pathophysiology of these syndromes. However, the functional role of these adhesion molecules in the thrombotic process remains unclear. Therefore, we investigated effects of SLe(x)-OS on CFVs, platelet P-selectin expression, and morphology of the stenotic site in the same model. Anesthetized open-chest dogs (n=34) were randomly divided into 4 groups after developing CFVs. Dogs intravenously received saline or graded doses of SLe(x)-OS (5, 20, or 40 mg/kg bolus) infusion followed by a continuous infusion (5 mg. kg-1. h-1) for 60 minutes. By flow cytometric analysis, P-selectin expression on platelets after CFVs was significantly upregulated during CFVs. Immunohistochemical analysis revealed the incorporation of platelets with upregulated P-selectin within thrombi at the stenotic site. Microscopic observations revealed the presence of numerous platelets adhered to leukocytes at the stenotic site on the damaged endothelium. SLe(x)-OS significantly reduced CFVs, inhibited the P-selectin expression on platelets, and prevented the adherence of platelets and leukocytes. These findings further support the notion that the adhesive interaction between P-selectin on platelets and SLe(x) on leukocytes plays an important role in platelet-mediated thrombus formation in this model.  (+info)

Coronary thrombosis is a medical condition that refers to the formation of a blood clot (thrombus) inside a coronary artery, which supplies oxygenated blood to the heart muscle. The development of a thrombus can partially or completely obstruct blood flow, leading to insufficient oxygen supply to the heart muscle. This can cause chest pain (angina) or a heart attack (myocardial infarction), depending on the severity and duration of the blockage.

Coronary thrombosis often results from the rupture of an atherosclerotic plaque, a buildup of cholesterol, fat, calcium, and other substances in the inner lining (endothelium) of the coronary artery. The ruptured plaque exposes the underlying tissue to the bloodstream, triggering the coagulation cascade and resulting in the formation of a thrombus.

Immediate medical attention is crucial for managing coronary thrombosis, as timely treatment can help restore blood flow, prevent further damage to the heart muscle, and reduce the risk of complications such as heart failure or life-threatening arrhythmias. Treatment options may include medications, such as antiplatelet agents, anticoagulants, and thrombolytic drugs, or interventional procedures like angioplasty and stenting to open the blocked artery. In some cases, surgical intervention, such as coronary artery bypass grafting (CABG), may be necessary.

Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a clot forms in an artery, it can cut off the supply of oxygen and nutrients to the tissues served by that artery, leading to damage or tissue death. If a thrombus forms in the heart, it can cause a heart attack. If a thrombus breaks off and travels through the bloodstream, it can lodge in a smaller vessel, causing blockage and potentially leading to damage in the organ that the vessel supplies. This is known as an embolism.

Thrombosis can occur due to various factors such as injury to the blood vessel wall, abnormalities in blood flow, or changes in the composition of the blood. Certain medical conditions, medications, and lifestyle factors can increase the risk of thrombosis. Treatment typically involves anticoagulant or thrombolytic therapy to dissolve or prevent further growth of the clot, as well as addressing any underlying causes.

Coronary vessels refer to the network of blood vessels that supply oxygenated blood and nutrients to the heart muscle, also known as the myocardium. The two main coronary arteries are the left main coronary artery and the right coronary artery.

The left main coronary artery branches off into the left anterior descending artery (LAD) and the left circumflex artery (LCx). The LAD supplies blood to the front of the heart, while the LCx supplies blood to the side and back of the heart.

The right coronary artery supplies blood to the right lower part of the heart, including the right atrium and ventricle, as well as the back of the heart.

Coronary vessel disease (CVD) occurs when these vessels become narrowed or blocked due to the buildup of plaque, leading to reduced blood flow to the heart muscle. This can result in chest pain, shortness of breath, or a heart attack.

Coronary angiography is a medical procedure that uses X-ray imaging to visualize the coronary arteries, which supply blood to the heart muscle. During the procedure, a thin, flexible catheter is inserted into an artery in the arm or groin and threaded through the blood vessels to the heart. A contrast dye is then injected through the catheter, and X-ray images are taken as the dye flows through the coronary arteries. These images can help doctors diagnose and treat various heart conditions, such as blockages or narrowing of the arteries, that can lead to chest pain or heart attacks. It is also known as coronary arteriography or cardiac catheterization.

Venous thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) in the deep veins, often in the legs (deep vein thrombosis or DVT), but it can also occur in other parts of the body such as the arms, pelvis, or lungs (pulmonary embolism).

The formation of a venous thrombus can be caused by various factors, including injury to the blood vessel wall, changes in blood flow, and alterations in the composition of the blood. These factors can lead to the activation of clotting factors and platelets, which can result in the formation of a clot that blocks the vein.

Symptoms of venous thrombosis may include swelling, pain, warmth, and redness in the affected area. In some cases, the clot can dislodge and travel to other parts of the body, causing potentially life-threatening complications such as pulmonary embolism.

Risk factors for venous thrombosis include advanced age, obesity, smoking, pregnancy, use of hormonal contraceptives or hormone replacement therapy, cancer, recent surgery or trauma, prolonged immobility, and a history of previous venous thromboembolism. Treatment typically involves the use of anticoagulant medications to prevent further clotting and dissolve existing clots.

Coronary circulation refers to the circulation of blood in the coronary vessels, which supply oxygenated blood to the heart muscle (myocardium) and drain deoxygenated blood from it. The coronary circulation system includes two main coronary arteries - the left main coronary artery and the right coronary artery - that branch off from the aorta just above the aortic valve. These arteries further divide into smaller branches, which supply blood to different regions of the heart muscle.

The left main coronary artery divides into two branches: the left anterior descending (LAD) artery and the left circumflex (LCx) artery. The LAD supplies blood to the front and sides of the heart, while the LCx supplies blood to the back and sides of the heart. The right coronary artery supplies blood to the lower part of the heart, including the right ventricle and the bottom portion of the left ventricle.

The veins that drain the heart muscle include the great cardiac vein, the middle cardiac vein, and the small cardiac vein, which merge to form the coronary sinus. The coronary sinus empties into the right atrium, allowing deoxygenated blood to enter the right side of the heart and be pumped to the lungs for oxygenation.

Coronary circulation is essential for maintaining the health and function of the heart muscle, as it provides the necessary oxygen and nutrients required for proper contraction and relaxation of the myocardium. Any disruption or blockage in the coronary circulation system can lead to serious consequences, such as angina, heart attack, or even death.

Coronary artery disease (CAD) is a medical condition in which the coronary arteries, which supply oxygen-rich blood to the heart muscle, become narrowed or blocked due to the buildup of cholesterol, fatty deposits, and other substances, known as plaque. Over time, this buildup can cause the arteries to harden and narrow (a process called atherosclerosis), reducing blood flow to the heart muscle.

The reduction in blood flow can lead to various symptoms and complications, including:

1. Angina (chest pain or discomfort) - This occurs when the heart muscle doesn't receive enough oxygen-rich blood, causing pain, pressure, or discomfort in the chest, arms, neck, jaw, or back.
2. Shortness of breath - When the heart isn't receiving adequate blood flow, it can't pump blood efficiently to meet the body's demands, leading to shortness of breath during physical activities or at rest.
3. Heart attack - If a piece of plaque ruptures or breaks off in a coronary artery, a blood clot can form and block the artery, causing a heart attack (myocardial infarction). This can damage or destroy part of the heart muscle.
4. Heart failure - Chronic reduced blood flow to the heart muscle can weaken it over time, leading to heart failure, a condition in which the heart can't pump blood efficiently to meet the body's needs.
5. Arrhythmias - Reduced blood flow and damage to the heart muscle can lead to abnormal heart rhythms (arrhythmias), which can be life-threatening if not treated promptly.

Coronary artery disease is typically diagnosed through a combination of medical history, physical examination, and diagnostic tests such as electrocardiograms (ECGs), stress testing, cardiac catheterization, and imaging studies like coronary computed tomography angiography (CCTA). Treatment options for CAD include lifestyle modifications, medications, medical procedures, and surgery.

Coronary balloon angioplasty is a minimally invasive medical procedure used to widen narrowed or obstructed coronary arteries (the blood vessels that supply oxygen-rich blood to the heart muscle) and improve blood flow to the heart. This procedure is typically performed in conjunction with the insertion of a stent, a small mesh tube that helps keep the artery open.

During coronary balloon angioplasty, a thin, flexible catheter with a deflated balloon at its tip is inserted into a blood vessel, usually through a small incision in the groin or arm. The catheter is then guided to the narrowed or obstructed section of the coronary artery. Once in position, the balloon is inflated to compress the plaque against the artery wall and widen the lumen (the inner space) of the artery. This helps restore blood flow to the heart muscle.

The procedure is typically performed under local anesthesia and conscious sedation to minimize discomfort. Coronary balloon angioplasty is a relatively safe and effective treatment for many people with coronary artery disease, although complications such as bleeding, infection, or re-narrowing of the artery (restenosis) can occur in some cases.

Myocardial infarction (MI), also known as a heart attack, is a medical condition characterized by the death of a segment of heart muscle (myocardium) due to the interruption of its blood supply. This interruption is most commonly caused by the blockage of a coronary artery by a blood clot formed on the top of an atherosclerotic plaque, which is a buildup of cholesterol and other substances in the inner lining of the artery.

The lack of oxygen and nutrients supply to the heart muscle tissue results in damage or death of the cardiac cells, causing the affected area to become necrotic. The extent and severity of the MI depend on the size of the affected area, the duration of the occlusion, and the presence of collateral circulation.

Symptoms of a myocardial infarction may include chest pain or discomfort, shortness of breath, nausea, lightheadedness, and sweating. Immediate medical attention is necessary to restore blood flow to the affected area and prevent further damage to the heart muscle. Treatment options for MI include medications, such as thrombolytics, antiplatelet agents, and pain relievers, as well as procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

Coronary artery disease, often simply referred to as coronary disease, is a condition in which the blood vessels that supply oxygen-rich blood to the heart become narrowed or blocked due to the buildup of fatty deposits called plaques. This can lead to chest pain (angina), shortness of breath, or in severe cases, a heart attack.

The medical definition of coronary artery disease is:

A condition characterized by the accumulation of atheromatous plaques in the walls of the coronary arteries, leading to decreased blood flow and oxygen supply to the myocardium (heart muscle). This can result in symptoms such as angina pectoris, shortness of breath, or arrhythmias, and may ultimately lead to myocardial infarction (heart attack) or heart failure.

Risk factors for coronary artery disease include age, smoking, high blood pressure, high cholesterol, diabetes, obesity, physical inactivity, and a family history of the condition. Lifestyle changes such as quitting smoking, exercising regularly, eating a healthy diet, and managing stress can help reduce the risk of developing coronary artery disease. Medical treatments may include medications to control blood pressure, cholesterol levels, or irregular heart rhythms, as well as procedures such as angioplasty or bypass surgery to improve blood flow to the heart.

Hirudin therapy, also known as leech therapy, is a type of treatment that uses the saliva of medicinal leeches (Hirudo medicinalis) to alleviate symptoms and promote healing. The saliva of these leeches contains various bioactive compounds, including hirudin, which is a potent anticoagulant that prevents blood clotting.

In hirudin therapy, leeches are applied to specific areas of the body, usually on congested tissues or sites of stasis, where they feed on the patient's blood and release their saliva into the bite site. The hirudin in the saliva helps to dissolve blood clots, improve circulation, reduce swelling, and relieve pain.

Hirudin therapy is used in various medical conditions, such as arterial and venous insufficiency, skin ulcers, joint diseases, and post-surgical recovery, particularly after reconstructive surgery or organ transplantation. It can also be used to treat thrombophlebitis, varicose veins, and other circulatory disorders.

It is essential to note that hirudin therapy should only be performed by trained medical professionals in a controlled environment due to the potential risks associated with infection transmission and bleeding complications.

Amrinone is a pharmacological agent, specifically a positive inotrope, that is used in the treatment of heart failure. It works by increasing the force of heart muscle contractions and improving cardiac output. Amrinone belongs to a class of drugs called phosphodiesterase inhibitors, which increase cyclic AMP levels in the heart, leading to increased contractility.

Here is the medical definition of 'Amrinone':

Amrinone: A synthetic cardiac drug that acts as a positive inotrope and vasodilator. It works by increasing the force of heart muscle contractions and reducing afterload, which improves cardiac output. Amrinone inhibits phosphodiesterase III, leading to increased intracellular cyclic AMP levels and enhanced calcium sensitivity in myocardial cells. It is used in the treatment of congestive heart failure and is administered intravenously.

Dibenzothiepins are a class of chemical compounds that contain a dibenzothiepin ring structure. This ring structure is composed of two benzene rings fused to a thiepin ring, which is a six-membered ring containing a sulfur atom and a double bond.

In the medical field, dibenzothiepins are primarily known for their use as antipsychotic drugs. The first dibenzothiepin antipsychotic, clopenthixol, was synthesized in the 1960s and found to have potent antipsychotic effects. Since then, several other dibenzothiepins have been developed for use as antipsychotics, including flupentixol and thiothixene.

These drugs work by blocking dopamine receptors in the brain, which helps to reduce the symptoms of psychosis such as hallucinations, delusions, and disorganized thinking. However, they can also cause side effects such as extrapyramidal symptoms (involuntary muscle movements), sedation, and weight gain.

It's worth noting that while dibenzothiepins have been used as antipsychotics for several decades, they are not commonly prescribed today due to the availability of newer antipsychotic drugs with fewer side effects.

I believe there might be a misunderstanding in your question. "Dogs" is not a medical term or condition. It is the common name for a domesticated carnivore of the family Canidae, specifically the genus Canis, which includes wolves, foxes, and other extant and extinct species of mammals. Dogs are often kept as pets and companions, and they have been bred in a wide variety of forms and sizes for different purposes, such as hunting, herding, guarding, assisting police and military forces, and providing companionship and emotional support.

If you meant to ask about a specific medical condition or term related to dogs, please provide more context so I can give you an accurate answer.

Fibrinolytic agents are medications that dissolve or break down blood clots by activating plasminogen, which is converted into plasmin. Plasmin is a proteolytic enzyme that degrades fibrin, the structural protein in blood clots. Fibrinolytic agents are used medically to treat conditions such as acute ischemic stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction (heart attack) by restoring blood flow in occluded vessels. Examples of fibrinolytic agents include alteplase, reteplase, and tenecteplase. It is important to note that these medications carry a risk of bleeding complications and should be administered with caution.

Coronary stenosis is a medical condition that refers to the narrowing of the coronary arteries, which supply oxygen-rich blood to the heart muscle. This narrowing is typically caused by the buildup of plaque, made up of fat, cholesterol, and other substances, on the inner walls of the arteries. Over time, as the plaque hardens and calcifies, it can cause the artery to become narrowed or blocked, reducing blood flow to the heart muscle.

Coronary stenosis can lead to various symptoms and complications, including chest pain (angina), shortness of breath, irregular heart rhythms (arrhythmias), and heart attacks. Treatment options for coronary stenosis may include lifestyle changes, medications, medical procedures such as angioplasty or bypass surgery, or a combination of these approaches. Regular check-ups and diagnostic tests, such as stress testing or coronary angiography, can help detect and monitor coronary stenosis over time.

Thromboxane-A Synthase (TXA2S) is a medical term referring to an enzyme that plays a crucial role in the blood coagulation process. It is found in platelets, and its primary function is to convert arachidonic acid into thromboxane A2 (TXA2), a potent vasoconstrictor and platelet aggregator.

Thromboxane A2 causes platelets to clump together, which is essential for the formation of blood clots that can help prevent excessive bleeding after an injury. However, an overproduction of thromboxane A2 can lead to the development of blood clots in blood vessels, increasing the risk of heart attack and stroke.

Therefore, Thromboxane-A Synthase is a vital enzyme in hemostasis (the process that stops bleeding), but its dysregulation can contribute to various cardiovascular diseases.

Coronary artery bypass surgery, also known as coronary artery bypass grafting (CABG), is a surgical procedure used to improve blood flow to the heart in patients with severe coronary artery disease. This condition occurs when the coronary arteries, which supply oxygen-rich blood to the heart muscle, become narrowed or blocked due to the buildup of fatty deposits, called plaques.

During CABG surgery, a healthy blood vessel from another part of the body is grafted, or attached, to the coronary artery, creating a new pathway for oxygen-rich blood to flow around the blocked or narrowed portion of the artery and reach the heart muscle. This bypass helps to restore normal blood flow and reduce the risk of angina (chest pain), shortness of breath, and other symptoms associated with coronary artery disease.

There are different types of CABG surgery, including traditional on-pump CABG, off-pump CABG, and minimally invasive CABG. The choice of procedure depends on various factors, such as the patient's overall health, the number and location of blocked arteries, and the presence of other medical conditions.

It is important to note that while CABG surgery can significantly improve symptoms and quality of life in patients with severe coronary artery disease, it does not cure the underlying condition. Lifestyle modifications, such as regular exercise, a healthy diet, smoking cessation, and medication therapy, are essential for long-term management and prevention of further progression of the disease.

Platelet aggregation is the clumping together of platelets (thrombocytes) in the blood, which is an essential step in the process of hemostasis (the stopping of bleeding) after injury to a blood vessel. When the inner lining of a blood vessel is damaged, exposure of subendothelial collagen and tissue factor triggers platelet activation. Activated platelets change shape, become sticky, and release the contents of their granules, which include ADP (adenosine diphosphate).

ADP then acts as a chemical mediator to attract and bind additional platelets to the site of injury, leading to platelet aggregation. This forms a plug that seals the damaged vessel and prevents further blood loss. Platelet aggregation is also a crucial component in the formation of blood clots (thrombosis) within blood vessels, which can have pathological consequences such as heart attacks and strokes if they obstruct blood flow to vital organs.

Platelet aggregation inhibitors are a class of medications that prevent platelets (small blood cells involved in clotting) from sticking together and forming a clot. These drugs work by interfering with the ability of platelets to adhere to each other and to the damaged vessel wall, thereby reducing the risk of thrombosis (blood clot formation).

Platelet aggregation inhibitors are often prescribed for people who have an increased risk of developing blood clots due to various medical conditions such as atrial fibrillation, coronary artery disease, peripheral artery disease, stroke, or a history of heart attack. They may also be used in patients undergoing certain medical procedures, such as angioplasty and stenting, to prevent blood clot formation in the stents.

Examples of platelet aggregation inhibitors include:

1. Aspirin: A nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase, which is involved in platelet activation and aggregation.
2. Clopidogrel (Plavix): A P2Y12 receptor antagonist that selectively blocks ADP-induced platelet activation and aggregation.
3. Prasugrel (Effient): A third-generation thienopyridine P2Y12 receptor antagonist, similar to clopidogrel but with faster onset and greater potency.
4. Ticagrelor (Brilinta): A direct-acting P2Y12 receptor antagonist that does not require metabolic activation and has a reversible binding profile.
5. Dipyridamole (Persantine): An antiplatelet agent that inhibits platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels in platelets, which leads to decreased platelet reactivity.
6. Iloprost (Ventavis): A prostacyclin analogue that inhibits platelet aggregation and causes vasodilation, often used in the treatment of pulmonary arterial hypertension.
7. Cilostazol (Pletal): A phosphodiesterase III inhibitor that increases cAMP levels in platelets, leading to decreased platelet activation and aggregation, as well as vasodilation.
8. Ticlopidine (Ticlid): An older P2Y12 receptor antagonist with a slower onset of action and more frequent side effects compared to clopidogrel or prasugrel.

Tissue Plasminogen Activator (tPA) is a thrombolytic enzyme, which means it dissolves blood clots. It is naturally produced by the endothelial cells that line the interior surface of blood vessels. tPA activates plasminogen, a zymogen, to convert it into plasmin, a protease that breaks down fibrin, the structural protein in blood clots. This enzyme is used medically as a thrombolytic drug under various brand names, such as Activase and Alteplase, to treat conditions like acute ischemic stroke, pulmonary embolism, and deep vein thrombosis by dissolving the clots and restoring blood flow.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Intracranial sinus thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) within the intracranial venous sinuses, which are responsible for draining blood from the brain. The condition can lead to various neurological symptoms and complications, such as increased intracranial pressure, headaches, seizures, visual disturbances, and altered consciousness. Intracranial sinus thrombosis may result from various factors, including hypercoagulable states, infections, trauma, and malignancies. Immediate medical attention is necessary for proper diagnosis and treatment to prevent potential long-term neurological damage or even death.

Unstable angina is a term used in cardiology to describe chest pain or discomfort that occurs suddenly and unexpectedly, often at rest or with minimal physical exertion. It is caused by an insufficient supply of oxygen-rich blood to the heart muscle due to reduced blood flow, typically as a result of partial or complete blockage of the coronary arteries.

Unlike stable angina, which tends to occur predictably during physical activity and can be relieved with rest or nitroglycerin, unstable angina is more severe, unpredictable, and may not respond to traditional treatments. It is considered a medical emergency because it can be a sign of an impending heart attack or other serious cardiac event.

Unstable angina is often treated in the hospital with medications such as nitroglycerin, beta blockers, calcium channel blockers, and antiplatelet agents to improve blood flow to the heart and prevent further complications. In some cases, more invasive treatments such as coronary angioplasty or bypass surgery may be necessary to restore blood flow to the affected areas of the heart.

The platelet glycoprotein GPIIb-IIIa complex, also known as integrin αIIbβ3 or CD41/CD61, is a heterodimeric transmembrane receptor found on the surface of platelets and megakaryocytes. It plays a crucial role in platelet aggregation and thrombus formation during hemostasis and pathological conditions such as arterial thrombosis.

The GPIIb-IIIa complex is composed of two non-covalently associated subunits, GPIIb (αIIb or CD41) and IIIa (β3 or CD61). Upon platelet activation by various agonists like ADP, thrombin, or collagen, the GPIIb-IIIa complex undergoes a conformational change that allows it to bind fibrinogen, von Willebrand factor, and other adhesive proteins. This binding event leads to platelet aggregation and the formation of a hemostatic plug or pathological thrombus.

Inhibition of the GPIIb-IIIa complex has been a target for antiplatelet therapy in the prevention and treatment of arterial thrombosis, such as myocardial infarction and stroke. Several pharmacological agents, including monoclonal antibodies and small molecule antagonists, have been developed to block this complex and reduce platelet aggregation.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Fibrinogen is a soluble protein present in plasma, synthesized by the liver. It plays an essential role in blood coagulation. When an injury occurs, fibrinogen gets converted into insoluble fibrin by the action of thrombin, forming a fibrin clot that helps to stop bleeding from the injured site. Therefore, fibrinogen is crucial for hemostasis, which is the process of stopping bleeding and starting the healing process after an injury.

Blood platelets, also known as thrombocytes, are small, colorless cell fragments in our blood that play an essential role in normal blood clotting. They are formed in the bone marrow from large cells called megakaryocytes and circulate in the blood in an inactive state until they are needed to help stop bleeding. When a blood vessel is damaged, platelets become activated and change shape, releasing chemicals that attract more platelets to the site of injury. These activated platelets then stick together to form a plug, or clot, that seals the wound and prevents further blood loss. In addition to their role in clotting, platelets also help to promote healing by releasing growth factors that stimulate the growth of new tissue.

Thrombolytic therapy, also known as thrombolysis, is a medical treatment that uses medications called thrombolytics or fibrinolytics to dissolve or break down blood clots (thrombi) in blood vessels. These clots can obstruct the flow of blood to vital organs such as the heart, lungs, or brain, leading to serious conditions like myocardial infarction (heart attack), pulmonary embolism, or ischemic stroke.

The goal of thrombolytic therapy is to restore blood flow as quickly and efficiently as possible to prevent further damage to the affected organ and potentially save lives. Commonly used thrombolytic drugs include alteplase (tPA), reteplase, and tenecteplase. It's essential to administer these medications as soon as possible after the onset of symptoms for optimal treatment outcomes. However, there are risks associated with thrombolytic therapy, such as an increased chance of bleeding complications, which must be carefully weighed against its benefits in each individual case.

Aspirin is the common name for acetylsalicylic acid, which is a medication used to relieve pain, reduce inflammation, and lower fever. It works by inhibiting the activity of an enzyme called cyclooxygenase (COX), which is involved in the production of prostaglandins, hormone-like substances that cause inflammation and pain. Aspirin also has an antiplatelet effect, which means it can help prevent blood clots from forming. This makes it useful for preventing heart attacks and strokes.

Aspirin is available over-the-counter in various forms, including tablets, capsules, and chewable tablets. It is also available in prescription strengths for certain medical conditions. As with any medication, aspirin should be taken as directed by a healthcare provider, and its use should be avoided in children and teenagers with viral infections due to the risk of Reye's syndrome, a rare but serious condition that can affect the liver and brain.

Coronary vasospasm refers to a sudden constriction (narrowing) of the coronary arteries, which supply oxygenated blood to the heart muscle. This constriction can reduce or block blood flow, leading to symptoms such as chest pain (angina) or, in severe cases, a heart attack (myocardial infarction). Coronary vasospasm can occur spontaneously or be triggered by various factors, including stress, smoking, and certain medications. It is also associated with conditions such as coronary artery disease and variant angina. Prolonged or recurrent vasospasms can cause damage to the heart muscle and increase the risk of cardiovascular events.

Intracranial thrombosis refers to the formation of a blood clot (thrombus) within the intracranial vessels, which supply blood to the brain. This condition can occur in any of the cerebral arteries or veins and can lead to serious complications such as ischemic stroke, transient ischemic attack (TIA), or venous sinus thrombosis.

The formation of an intracranial thrombus can be caused by various factors, including atherosclerosis, cardiac embolism, vasculitis, sickle cell disease, hypercoagulable states, and head trauma. Symptoms may vary depending on the location and extent of the thrombosis but often include sudden onset of headache, weakness or numbness in the face or limbs, difficulty speaking or understanding speech, vision changes, and loss of balance or coordination.

Diagnosis of intracranial thrombosis typically involves imaging studies such as computed tomography (CT) angiography, magnetic resonance angiography (MRA), or digital subtraction angiography (DSA). Treatment options may include anticoagulation therapy, thrombolysis, endovascular intervention, or surgical intervention, depending on the underlying cause and severity of the condition.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

Carotid artery thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) inside the carotid artery, which is one of the major blood vessels that supplies oxygenated blood to the head and neck. This condition can lead to serious complications such as a stroke or transient ischemic attack (TIA), also known as a "mini-stroke," if the clot dislodges and travels to the brain, blocking the flow of blood and oxygen.

Carotid artery thrombosis can result from various factors, including atherosclerosis (the buildup of fats, cholesterol, and other substances in the artery walls), hypertension (high blood pressure), diabetes, smoking, and genetic predisposition. Symptoms may include neck pain or stiffness, weakness or numbness in the face or limbs, difficulty speaking or understanding speech, vision problems, and sudden severe headaches. Diagnosis typically involves imaging tests such as ultrasound, CT angiography, or MRI angiography. Treatment options may include anticoagulant or antiplatelet medications, endovascular procedures to remove the clot, or surgery to clean out the artery (carotid endarterectomy).

A coronary aneurysm is a localized dilation or bulging of a portion of the wall of a coronary artery, which supplies blood to the muscle tissue of the heart. It's similar to a bubble or balloon-like structure that forms within the artery wall due to weakness in the arterial wall, leading to abnormal enlargement or widening.

Coronary aneurysms can vary in size and may be classified as true or false aneurysms based on their structure. True aneurysms involve all three layers of the artery wall, while false aneurysms (also known as pseudoaneurysms) only have one or two layers involved, with the remaining layer disrupted.

These aneurysms can lead to complications such as blood clots forming inside the aneurysm sac, which can then dislodge and cause blockages in smaller coronary arteries (embolism). Additionally, coronary aneurysms may rupture, leading to severe internal bleeding and potentially life-threatening situations.

Coronary aneurysms are often asymptomatic but can present with symptoms such as chest pain, shortness of breath, or palpitations, especially if the aneurysm causes a significant narrowing (stenosis) in the affected artery. They can be diagnosed through imaging techniques like coronary angiography, computed tomography (CT), or magnetic resonance imaging (MRI). Treatment options include medications to manage symptoms and prevent complications, as well as surgical interventions such as stenting or bypass grafting to repair or reroute the affected artery.

Electrocardiography (ECG or EKG) is a medical procedure that records the electrical activity of the heart. It provides a graphic representation of the electrical changes that occur during each heartbeat. The resulting tracing, called an electrocardiogram, can reveal information about the heart's rate and rhythm, as well as any damage to its cells or abnormalities in its conduction system.

During an ECG, small electrodes are placed on the skin of the chest, arms, and legs. These electrodes detect the electrical signals produced by the heart and transmit them to a machine that amplifies and records them. The procedure is non-invasive, painless, and quick, usually taking only a few minutes.

ECGs are commonly used to diagnose and monitor various heart conditions, including arrhythmias, coronary artery disease, heart attacks, and electrolyte imbalances. They can also be used to evaluate the effectiveness of certain medications or treatments.

Coronary restenosis is the re-narrowing or re-occlusion of a coronary artery after a previous successful procedure to open or widen the artery, such as angioplasty or stenting. This narrowing is usually caused by the excessive growth of scar tissue or smooth muscle cells in the artery lining, which can occur spontaneously or as a response to the initial procedure. Restenosis can lead to recurrent symptoms of coronary artery disease, such as chest pain or shortness of breath, and may require additional medical intervention.

Coronary occlusion is the medical term used to describe a complete blockage in one or more of the coronary arteries, which supply oxygenated blood to the heart muscle. This blockage is usually caused by the buildup of fatty deposits, called plaques, inside the artery walls, a condition known as atherosclerosis. Over time, these plaques can rupture, leading to the formation of blood clots that completely obstruct the flow of blood through the coronary artery.

Coronary occlusion can lead to serious complications, such as a heart attack (myocardial infarction), angina (chest pain), or even sudden cardiac death, depending on the severity and duration of the blockage. Immediate medical attention is required in case of coronary occlusion to restore blood flow to the affected areas of the heart and prevent further damage. Treatment options may include medications, minimally invasive procedures like angioplasty and stenting, or surgical interventions such as coronary artery bypass grafting (CABG).

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

A stent is a small mesh tube that's used to treat narrow or weak arteries. Arteries are blood vessels that carry blood away from your heart to other parts of your body. A stent is placed in an artery as part of a procedure called angioplasty. Angioplasty restores blood flow through narrowed or blocked arteries by inflating a tiny balloon inside the blocked artery to widen it.

The stent is then inserted into the widened artery to keep it open. The stent is usually made of metal, but some are coated with medication that is slowly and continuously released to help prevent the formation of scar tissue in the artery. This can reduce the chance of the artery narrowing again.

Stents are also used in other parts of the body, such as the neck (carotid artery) and kidneys (renal artery), to help maintain blood flow and prevent blockages. They can also be used in the urinary system to treat conditions like ureteropelvic junction obstruction or narrowing of the urethra.

Percutaneous Coronary Intervention (PCI), also known as coronary angioplasty, is a non-surgical procedure that opens up clogged coronary arteries to improve blood flow to the heart. It involves inserting a thin, flexible catheter into an artery in the groin or wrist and guiding it to the blocked artery in the heart. A small balloon is then inflated to widen the narrowed or blocked artery, and sometimes a stent (a tiny mesh tube) is placed to keep the artery open. This procedure helps to restore and maintain blood flow to the heart muscle, reducing symptoms of angina and improving overall cardiac function.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Phlebography is a medical imaging technique used to visualize and assess the veins, particularly in the legs. It involves the injection of a contrast agent into the veins, followed by X-ray imaging to capture the flow of the contrast material through the veins. This allows doctors to identify any abnormalities such as blood clots, blockages, or malformations in the venous system.

There are different types of phlebography, including ascending phlebography (where the contrast agent is injected into a foot vein and travels up the leg) and descending phlebography (where the contrast agent is injected into a vein in the groin or neck and travels down the leg).

Phlebography is an invasive procedure that requires careful preparation and monitoring, and it is typically performed by radiologists or vascular specialists. It has largely been replaced by non-invasive imaging techniques such as ultrasound and CT angiography in many clinical settings.

Sagittal sinus thrombosis is a medical condition that refers to the formation of a blood clot (thrombus) in the sagittal sinus, which is a venous structure located in the brain. The sagittal sinus runs along the midline of the brain and receives blood from the superficial veins of the brain.

Sagittal sinus thrombosis can occur as a result of various conditions, such as head trauma, infection, cancer, or certain medical disorders that cause hypercoagulability (an increased tendency to form blood clots). The formation of a blood clot in the sagittal sinus can obstruct the flow of blood from the brain, leading to symptoms such as headache, seizures, altered consciousness, and focal neurological deficits.

Diagnosis of sagittal sinus thrombosis typically involves imaging studies such as computed tomography (CT) or magnetic resonance imaging (MRI) scans, which can show the presence of a blood clot in the sagittal sinus. Treatment may involve administering anticoagulant medications to prevent further growth of the blood clot and reduce the risk of complications such as pulmonary embolism or cerebral infarction. In some cases, surgical intervention may be necessary to remove the blood clot or alleviate pressure on the brain.

Coronary Care Units (CCUs) are specialized hospital wards that provide intensive care to patients with severe, life-threatening heart conditions. These units are equipped with advanced monitoring and treatment technologies to continuously monitor a patient's cardiac function and provide immediate medical interventions when necessary. Common conditions treated in CCUs include acute myocardial infarction (heart attack), unstable angina, cardiac arrhythmias, and heart failure. The primary goal of a CCU is to stabilize the patient's condition, prevent further complications, and facilitate recovery.

1. Intracranial Embolism: This is a medical condition that occurs when a blood clot or other particle (embolus) formed elsewhere in the body, travels through the bloodstream and lodges itself in the intracranial blood vessels, blocking the flow of blood to a part of the brain. This can lead to various neurological symptoms such as weakness, numbness, speech difficulties, or even loss of consciousness, depending on the severity and location of the blockage.

2. Intracranial Thrombosis: This is a medical condition that occurs when a blood clot (thrombus) forms within the intracranial blood vessels. The clot can partially or completely obstruct the flow of blood, leading to various symptoms such as headache, confusion, seizures, or neurological deficits, depending on the severity and location of the thrombosis. Intracranial thrombosis can occur due to various factors including atherosclerosis, hypertension, diabetes, and other medical conditions that increase the risk of blood clot formation.

Interventional ultrasonography is a medical procedure that involves the use of real-time ultrasound imaging to guide minimally invasive diagnostic and therapeutic interventions. This technique combines the advantages of ultrasound, such as its non-ionizing nature (no radiation exposure), relatively low cost, and portability, with the ability to perform precise and targeted procedures.

In interventional ultrasonography, a specialized physician called an interventional radiologist or an interventional sonographer uses high-frequency sound waves to create detailed images of internal organs and tissues. These images help guide the placement of needles, catheters, or other instruments used during the procedure. Common interventions include biopsies (tissue sampling), fluid drainage, tumor ablation, and targeted drug delivery.

The real-time visualization provided by ultrasonography allows for increased accuracy and safety during these procedures, minimizing complications and reducing recovery time compared to traditional surgical approaches. Additionally, interventional ultrasonography can be performed on an outpatient basis, further contributing to its appeal as a less invasive alternative in many clinical scenarios.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Thrombophilia is a medical condition characterized by an increased tendency to form blood clots (thrombi) due to various genetic or acquired abnormalities in the coagulation system. These abnormalities can lead to a hypercoagulable state, which can cause thrombosis in both veins and arteries. Commonly identified thrombophilias include factor V Leiden mutation, prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, and protein S deficiency.

Acquired thrombophilias can be caused by various factors such as antiphospholipid antibody syndrome (APS), malignancies, pregnancy, oral contraceptive use, hormone replacement therapy, and certain medical conditions like inflammatory bowel disease or nephrotic syndrome.

It is essential to diagnose thrombophilia accurately, as it may influence the management of venous thromboembolism (VTE) events and guide decisions regarding prophylactic anticoagulation in high-risk situations.

Myocardial ischemia is a condition in which the blood supply to the heart muscle (myocardium) is reduced or blocked, leading to insufficient oxygen delivery and potential damage to the heart tissue. This reduction in blood flow typically results from the buildup of fatty deposits, called plaques, in the coronary arteries that supply the heart with oxygen-rich blood. The plaques can rupture or become unstable, causing the formation of blood clots that obstruct the artery and limit blood flow.

Myocardial ischemia may manifest as chest pain (angina pectoris), shortness of breath, fatigue, or irregular heartbeats (arrhythmias). In severe cases, it can lead to myocardial infarction (heart attack) if the oxygen supply is significantly reduced or cut off completely, causing permanent damage or death of the heart muscle. Early diagnosis and treatment of myocardial ischemia are crucial for preventing further complications and improving patient outcomes.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

The femoral vein is the large vein that runs through the thigh and carries oxygen-depleted blood from the lower limbs back to the heart. It is located in the femoral triangle, along with the femoral artery and nerve. The femoral vein begins at the knee as the popliteal vein, which then joins with the deep vein of the thigh to form the femoral vein. As it moves up the leg, it is joined by several other veins, including the great saphenous vein, before it becomes the external iliac vein at the inguinal ligament in the groin.

The iliac veins are a pair of large veins in the human body that carry deoxygenated blood from the lower extremities and the pelvic area back to the heart. They are formed by the union of the common iliac veins, which receive blood from the lower abdomen and legs, at the level of the fifth lumbar vertebra.

The combined iliac vein is called the inferior vena cava, which continues upward to the right atrium of the heart. The iliac veins are located deep within the pelvis, lateral to the corresponding iliac arteries, and are accompanied by the iliac lymphatic vessels.

The left common iliac vein is longer than the right because it must cross the left common iliac artery to join the right common iliac vein. The external and internal iliac veins are the two branches of the common iliac vein, with the external iliac vein carrying blood from the lower limbs and the internal iliac vein carrying blood from the pelvic organs.

It is essential to maintain proper blood flow in the iliac veins to prevent deep vein thrombosis (DVT), a condition that can lead to serious complications such as pulmonary embolism.

The Predictive Value of Tests, specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV), are measures used in diagnostic tests to determine the probability that a positive or negative test result is correct.

Positive Predictive Value (PPV) is the proportion of patients with a positive test result who actually have the disease. It is calculated as the number of true positives divided by the total number of positive results (true positives + false positives). A higher PPV indicates that a positive test result is more likely to be a true positive, and therefore the disease is more likely to be present.

Negative Predictive Value (NPV) is the proportion of patients with a negative test result who do not have the disease. It is calculated as the number of true negatives divided by the total number of negative results (true negatives + false negatives). A higher NPV indicates that a negative test result is more likely to be a true negative, and therefore the disease is less likely to be present.

The predictive value of tests depends on the prevalence of the disease in the population being tested, as well as the sensitivity and specificity of the test. A test with high sensitivity and specificity will generally have higher predictive values than a test with low sensitivity and specificity. However, even a highly sensitive and specific test can have low predictive values if the prevalence of the disease is low in the population being tested.

Risk assessment in the medical context refers to the process of identifying, evaluating, and prioritizing risks to patients, healthcare workers, or the community related to healthcare delivery. It involves determining the likelihood and potential impact of adverse events or hazards, such as infectious diseases, medication errors, or medical devices failures, and implementing measures to mitigate or manage those risks. The goal of risk assessment is to promote safe and high-quality care by identifying areas for improvement and taking action to minimize harm.

Upper extremity deep vein thrombosis (UEDVT) is a medical condition that refers to the formation of a blood clot (thrombus) in the deep veins located in the arm or shoulder. This condition can occur due to various reasons, including trauma, surgery, cancer, certain medications, and underlying medical conditions that increase the risk of blood clotting.

The deep veins are larger vessels that run through the body's muscles and are surrounded by fascia, a connective tissue. UEDVT can cause partial or complete blockage of blood flow in the affected vein, leading to swelling, pain, redness, warmth, and decreased function in the arm or hand. In some cases, the clot can break off and travel to the lungs, causing a potentially life-threatening condition called pulmonary embolism (PE).

Diagnosis of UEDVT typically involves a physical exam, medical history, and imaging tests such as ultrasound, CT scan, or MRI. Treatment may include anticoagulant medications to prevent the clot from growing or breaking off, thrombolytic therapy to dissolve the clot, or surgical intervention in severe cases. Compression stockings or other devices may also be used to help improve blood flow and reduce swelling.

Calcinosis is a medical condition characterized by the abnormal deposit of calcium salts in various tissues of the body, commonly under the skin or in the muscles and tendons. These calcium deposits can form hard lumps or nodules that can cause pain, inflammation, and restricted mobility. Calcinosis can occur as a complication of other medical conditions, such as autoimmune disorders, kidney disease, and hypercalcemia (high levels of calcium in the blood). In some cases, the cause of calcinosis may be unknown. Treatment for calcinosis depends on the underlying cause and may include medications to manage calcium levels, physical therapy, and surgical removal of large deposits.

Hemostasis is the physiological process that occurs to stop bleeding (bleeding control) when a blood vessel is damaged. This involves the interaction of platelets, vasoconstriction, and blood clotting factors leading to the formation of a clot. The ultimate goal of hemostasis is to maintain the integrity of the vascular system while preventing excessive blood loss.

Myocardial revascularization is a medical term that refers to the restoration of blood flow to the heart muscle (myocardium), typically through a surgical or interventional procedure. This is often performed in patients with coronary artery disease, where the buildup of plaque in the coronary arteries restricts blood flow to the heart muscle, causing symptoms such as chest pain (angina) or shortness of breath, and increasing the risk of a heart attack (myocardial infarction).

There are two main types of myocardial revascularization:

1. Coronary artery bypass grafting (CABG): This is a surgical procedure in which a healthy blood vessel from another part of the body is used to create a detour around the blocked or narrowed coronary artery, allowing blood to flow more freely to the heart muscle.
2. Percutaneous coronary intervention (PCI), also known as angioplasty and stenting: This is a minimally invasive procedure in which a thin catheter is inserted into an artery in the groin or arm and threaded up to the blocked or narrowed coronary artery. A balloon is then inflated to widen the artery, and a stent may be placed to keep it open.

Both procedures aim to improve symptoms, reduce the risk of heart attack, and prolong survival in appropriately selected patients with coronary artery disease.

Ticlopidine is defined as a platelet aggregation inhibitor drug, which works by preventing certain types of blood cells (platelets) from sticking together to form clots. It is used to reduce the risk of stroke and heart attack in patients who have already had a stroke or have peripheral arterial disease.

Ticlopidine is a thienopyridine derivative that selectively inhibits platelet activation and aggregation by blocking the ADP (adenosine diphosphate) receptor on the platelet surface. This action prevents the formation of platelet plugs, which can lead to the development of blood clots in the arteries.

Ticlopidine is available in oral form as tablets and is typically taken twice daily. Common side effects include diarrhea, skin rash, and itching. More serious side effects, such as neutropenia (low white blood cell count), thrombotic thrombocytopenic purpura (TTP), and aplastic anemia, are rare but can be life-threatening.

Due to the risk of serious side effects, ticlopidine is usually reserved for use in patients who cannot tolerate or have failed other antiplatelet therapies, such as aspirin or clopidogrel. It is important to monitor patients taking ticlopidine closely for signs of adverse reactions and to follow the prescribing instructions carefully.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

A thrombectomy is a medical procedure that involves the removal of a blood clot (thrombus) from a blood vessel. This is typically performed to restore blood flow in cases where the clot is causing significant blockage, which can lead to serious complications such as tissue damage or organ dysfunction.

During a thrombectomy, a surgeon makes an incision and accesses the affected blood vessel, often with the help of imaging guidance. Specialized tools are then used to extract the clot, after which the blood vessel is usually repaired. Thrombectomies can be performed on various blood vessels throughout the body, including those in the brain, heart, lungs, and limbs.

This procedure may be recommended for patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of stroke, depending on the specific circumstances and the patient's overall health. It is generally considered when anticoagulation therapy or clot-dissolving medications are not sufficient or appropriate to treat the blood clot.

The portal vein is the large venous trunk that carries blood from the gastrointestinal tract, spleen, pancreas, and gallbladder to the liver. It is formed by the union of the superior mesenteric vein (draining the small intestine and a portion of the large intestine) and the splenic vein (draining the spleen and pancreas). The portal vein then divides into right and left branches within the liver, where the blood flows through the sinusoids and gets enriched with oxygen and nutrients before being drained by the hepatic veins into the inferior vena cava. This unique arrangement allows the liver to process and detoxify the absorbed nutrients, remove waste products, and regulate metabolic homeostasis.

Coronary artery bypass, off-pump refers to a surgical procedure used to treat coronary artery disease (CAD), which is the narrowing or blockage of the coronary arteries due to the buildup of fatty deposits called plaques. This procedure is also known as off-pump coronary artery bypass (OPCAB) or beating heart bypass surgery.

In a coronary artery bypass, off-pump procedure, the surgeon creates a new pathway for blood to flow around the blocked or narrowed portion of the coronary artery using a healthy blood vessel from another part of the body, such as the chest wall (internal mammary artery) or the leg (saphenous vein). This allows oxygen-rich blood to bypass the blockage and reach the heart muscle directly.

The key difference between on-pump and off-pump coronary artery bypass surgery is that in an off-pump procedure, the heart continues to beat during the operation, and no heart-lung machine (cardiopulmonary bypass) is used. This approach has several potential advantages over on-pump CABG, including reduced risks of bleeding, stroke, and kidney failure. However, it may not be suitable for all patients, particularly those with complex or extensive coronary artery disease.

Overall, coronary artery bypass, off-pump surgery is a safe and effective treatment option for many patients with CAD, and can help improve symptoms, quality of life, and long-term outcomes.

Low-molecular-weight heparin (LMWH) is a type of heparin used as an anticoagulant, which refers to a group of medications that prevent the formation of blood clots. Heparin is a naturally occurring substance in the body, and low-molecular-weight heparins are obtained through the depolymerization of standard heparin.

LMWH has a lower molecular weight than standard heparin, which results in several pharmacological differences. LMWHs have a more predictable dose response, longer half-life, and higher bioavailability when administered subcutaneously compared to standard heparin. They also exhibit greater anti-factor Xa activity relative to their antithrombin (anti-IIa) activity, which contributes to their anticoagulant effects.

LMWHs are used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. Common LMWHs include enoxaparin, dalteparin, tinzaparin, and nadroparin.

It is essential to monitor the patient's kidney function when using LMWH since they are primarily cleared by the kidneys. In patients with renal impairment, dose adjustments or alternative anticoagulants may be necessary to reduce the risk of bleeding complications.

Cerebral veins are the blood vessels that carry deoxygenated blood from the brain to the dural venous sinuses, which are located between the layers of tissue covering the brain. The largest cerebral vein is the superior sagittal sinus, which runs along the top of the brain. Other major cerebral veins include the straight sinus, transverse sinus, sigmoid sinus, and cavernous sinus. These veins receive blood from smaller veins called venules that drain the surface and deep structures of the brain. The cerebral veins play an important role in maintaining normal circulation and pressure within the brain.

Hemodynamics is the study of how blood flows through the cardiovascular system, including the heart and the vascular network. It examines various factors that affect blood flow, such as blood volume, viscosity, vessel length and diameter, and pressure differences between different parts of the circulatory system. Hemodynamics also considers the impact of various physiological and pathological conditions on these variables, and how they in turn influence the function of vital organs and systems in the body. It is a critical area of study in fields such as cardiology, anesthesiology, and critical care medicine.

The endothelium is a thin layer of simple squamous epithelial cells that lines the interior surface of blood vessels, lymphatic vessels, and heart chambers. The vascular endothelium, specifically, refers to the endothelial cells that line the blood vessels. These cells play a crucial role in maintaining vascular homeostasis by regulating vasomotor tone, coagulation, platelet activation, inflammation, and permeability of the vessel wall. They also contribute to the growth and repair of the vascular system and are involved in various pathological processes such as atherosclerosis, hypertension, and diabetes.

Cardiac catheterization is a medical procedure used to diagnose and treat cardiovascular conditions. In this procedure, a thin, flexible tube called a catheter is inserted into a blood vessel in the arm or leg and threaded up to the heart. The catheter can be used to perform various diagnostic tests, such as measuring the pressure inside the heart chambers and assessing the function of the heart valves.

Cardiac catheterization can also be used to treat certain cardiovascular conditions, such as narrowed or blocked arteries. In these cases, a balloon or stent may be inserted through the catheter to open up the blood vessel and improve blood flow. This procedure is known as angioplasty or percutaneous coronary intervention (PCI).

Cardiac catheterization is typically performed in a hospital cardiac catheterization laboratory by a team of healthcare professionals, including cardiologists, radiologists, and nurses. The procedure may be done under local anesthesia with sedation or general anesthesia, depending on the individual patient's needs and preferences.

Overall, cardiac catheterization is a valuable tool in the diagnosis and treatment of various heart conditions, and it can help improve symptoms, reduce complications, and prolong life for many patients.

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the activation of Factor X to Factor Xa, which is a critical step in the coagulation cascade.

When blood vessels are damaged, the coagulation cascade is initiated to prevent excessive bleeding. During this process, Factor V is activated by thrombin, another protein involved in coagulation, and then forms a complex with activated Factor X and calcium ions on the surface of platelets or other cells. This complex converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Deficiency or dysfunction of Factor V can lead to bleeding disorders such as hemophilia B or factor V deficiency, while mutations in the gene encoding Factor V can increase the risk of thrombosis, as seen in the Factor V Leiden mutation.

Vasodilator agents are pharmacological substances that cause the relaxation or widening of blood vessels by relaxing the smooth muscle in the vessel walls. This results in an increase in the diameter of the blood vessels, which decreases vascular resistance and ultimately reduces blood pressure. Vasodilators can be further classified based on their site of action:

1. Systemic vasodilators: These agents cause a generalized relaxation of the smooth muscle in the walls of both arteries and veins, resulting in a decrease in peripheral vascular resistance and preload (the volume of blood returning to the heart). Examples include nitroglycerin, hydralazine, and calcium channel blockers.
2. Arterial vasodilators: These agents primarily affect the smooth muscle in arterial vessel walls, leading to a reduction in afterload (the pressure against which the heart pumps blood). Examples include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct vasodilators like sodium nitroprusside.
3. Venous vasodilators: These agents primarily affect the smooth muscle in venous vessel walls, increasing venous capacitance and reducing preload. Examples include nitroglycerin and other organic nitrates.

Vasodilator agents are used to treat various cardiovascular conditions such as hypertension, heart failure, angina, and pulmonary arterial hypertension. It is essential to monitor their use carefully, as excessive vasodilation can lead to orthostatic hypotension, reflex tachycardia, or fluid retention.

Graft occlusion in the context of vascular surgery refers to the complete or partial blockage of a blood vessel that has been surgically replaced or repaired with a graft. The graft can be made from either synthetic materials or autologous tissue (taken from another part of the patient's body).

Graft occlusion can occur due to various reasons, including:

1. Thrombosis: Formation of a blood clot within the graft, which can obstruct blood flow.
2. Intimal hyperplasia: Overgrowth of the inner lining (intima) of the graft or the adjacent native vessel, causing narrowing of the lumen and reducing blood flow.
3. Atherosclerosis: Deposition of cholesterol and other substances in the walls of the graft, leading to hardening and narrowing of the vessel.
4. Infection: Bacterial or fungal infection of the graft can cause inflammation, weakening, and ultimately occlusion of the graft.
5. Mechanical factors: Kinking, twisting, or compression of the graft can lead to obstruction of blood flow.

Graft occlusion is a significant complication following vascular surgery, as it can result in reduced perfusion to downstream tissues and organs, leading to ischemia (lack of oxygen supply) and potential tissue damage or loss.

Blood flow velocity is the speed at which blood travels through a specific part of the vascular system. It is typically measured in units of distance per time, such as centimeters per second (cm/s) or meters per second (m/s). Blood flow velocity can be affected by various factors, including cardiac output, vessel diameter, and viscosity of the blood. Measuring blood flow velocity is important in diagnosing and monitoring various medical conditions, such as heart disease, stroke, and peripheral vascular disease.

Cavernous sinus thrombosis is a medical condition that refers to the formation of a blood clot (thrombus) in the cavernous sinuses, which are located near the base of the brain and are important for draining blood from the face and brain. This condition can occur as a complication of an infection in the facial area or sinuses, or it can be associated with other medical conditions such as cancer or trauma.

Symptoms of cavernous sinus thrombosis may include headache, fever, eye pain, swelling or bulging of the eyes, double vision, and decreased vision. If left untreated, this condition can lead to serious complications such as meningitis, brain abscess, or even death. Treatment typically involves administering antibiotics to treat any underlying infection and anticoagulants to prevent further clot formation. In some cases, surgery may be necessary to remove the clot.

Thromboembolism is a medical condition that refers to the obstruction of a blood vessel by a thrombus (blood clot) that has formed elsewhere in the body and then been transported by the bloodstream to a narrower vessel, where it becomes lodged. This process can occur in various parts of the body, leading to different types of thromboembolisms:

1. Deep Vein Thrombosis (DVT): A thrombus forms in the deep veins, usually in the legs or pelvis, and then breaks off and travels to the lungs, causing a pulmonary embolism.
2. Pulmonary Embolism (PE): A thrombus formed elsewhere, often in the deep veins of the legs, dislodges and travels to the lungs, blocking one or more pulmonary arteries. This can lead to shortness of breath, chest pain, and potentially life-threatening complications if not treated promptly.
3. Cerebral Embolism: A thrombus formed in another part of the body, such as the heart or carotid artery, dislodges and travels to the brain, causing a stroke or transient ischemic attack (TIA).
4. Arterial Thromboembolism: A thrombus forms in an artery and breaks off, traveling to another part of the body and blocking blood flow to an organ or tissue, leading to potential damage or loss of function. Examples include mesenteric ischemia (intestinal damage due to blocked blood flow) and retinal artery occlusion (vision loss due to blocked blood flow in the eye).

Prevention, early detection, and appropriate treatment are crucial for managing thromboembolism and reducing the risk of severe complications.

Vasodilation is the widening or increase in diameter of blood vessels, particularly the involuntary relaxation of the smooth muscle in the tunica media (middle layer) of the arteriole walls. This results in an increase in blood flow and a decrease in vascular resistance. Vasodilation can occur due to various physiological and pathophysiological stimuli, such as local metabolic demands, neural signals, or pharmacological agents. It plays a crucial role in regulating blood pressure, tissue perfusion, and thermoregulation.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

The inferior vena cava (IVC) is the largest vein in the human body that carries deoxygenated blood from the lower extremities, pelvis, and abdomen to the right atrium of the heart. It is formed by the union of the left and right common iliac veins at the level of the fifth lumbar vertebra. The inferior vena cava is a retroperitoneal structure, meaning it lies behind the peritoneum, the lining that covers the abdominal cavity. It ascends through the posterior abdominal wall and passes through the central tendon of the diaphragm to enter the thoracic cavity.

The inferior vena cava is composed of three parts:

1. The infrarenal portion, which lies below the renal veins
2. The renal portion, which receives blood from the renal veins
3. The suprahepatic portion, which lies above the liver and receives blood from the hepatic veins before draining into the right atrium of the heart.

The inferior vena cava plays a crucial role in maintaining venous return to the heart and contributing to cardiovascular function.

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies in the blood. These antibodies are directed against phospholipids, a type of fat molecule found in cell membranes and plasma lipoproteins. The presence of these antibodies can lead to abnormal blood clotting, which can cause serious complications such as stroke, heart attack, deep vein thrombosis, and pulmonary embolism.

APS can occur either on its own (primary APS) or in conjunction with other autoimmune disorders, such as systemic lupus erythematosus (secondary APS). The exact cause of APS is not fully understood, but it is believed to involve a combination of genetic and environmental factors.

Symptoms of APS can vary widely depending on the location and severity of the blood clots. They may include:

* Recurrent miscarriages or stillbirths
* Blood clots in the legs, lungs, or other parts of the body
* Skin ulcers or lesions
* Headaches, seizures, or stroke-like symptoms
* Kidney problems
* Heart valve abnormalities

Diagnosis of APS typically involves blood tests to detect the presence of antiphospholipid antibodies. Treatment may include medications to prevent blood clots, such as anticoagulants and antiplatelet agents, as well as management of any underlying autoimmune disorders.

In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.

Fibrin(ogen) degradation products (FDPs) are a group of proteins that result from the breakdown of fibrinogen and fibrin, which are key components of blood clots. This process occurs during the normal physiological process of fibrinolysis, where clots are dissolved to maintain blood flow.

FDPs can be measured in the blood as a marker for the activation of the coagulation and fibrinolytic systems. Elevated levels of FDPs may indicate the presence of a disorder that causes abnormal clotting or bleeding, such as disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of cancer.

It is important to note that FDPs are not specific to any particular disorder and their measurement should be interpreted in conjunction with other clinical and laboratory findings.

"Swine" is a common term used to refer to even-toed ungulates of the family Suidae, including domestic pigs and wild boars. However, in a medical context, "swine" often appears in the phrase "swine flu," which is a strain of influenza virus that typically infects pigs but can also cause illness in humans. The 2009 H1N1 pandemic was caused by a new strain of swine-origin influenza A virus, which was commonly referred to as "swine flu." It's important to note that this virus is not transmitted through eating cooked pork products; it spreads from person to person, mainly through respiratory droplets produced when an infected person coughs or sneezes.

Sirolimus is a medication that belongs to a class of drugs called immunosuppressants. It is also known as rapamycin. Sirolimus works by inhibiting the mammalian target of rapamycin (mTOR), which is a protein that plays a key role in cell growth and division.

Sirolimus is primarily used to prevent rejection of transplanted organs, such as kidneys, livers, and hearts. It works by suppressing the activity of the immune system, which can help to reduce the risk of the body rejecting the transplanted organ. Sirolimus is often used in combination with other immunosuppressive drugs, such as corticosteroids and calcineurin inhibitors.

Sirolimus is also being studied for its potential therapeutic benefits in a variety of other conditions, including cancer, tuberous sclerosis complex, and lymphangioleiomyomatosis. However, more research is needed to fully understand the safety and efficacy of sirolimus in these contexts.

It's important to note that sirolimus can have significant side effects, including increased risk of infections, mouth sores, high blood pressure, and kidney damage. Therefore, it should only be used under the close supervision of a healthcare provider.

In medical terms, the heart is a muscular organ located in the thoracic cavity that functions as a pump to circulate blood throughout the body. It's responsible for delivering oxygen and nutrients to the tissues and removing carbon dioxide and other wastes. The human heart is divided into four chambers: two atria on the top and two ventricles on the bottom. The right side of the heart receives deoxygenated blood from the body and pumps it to the lungs, while the left side receives oxygenated blood from the lungs and pumps it out to the rest of the body. The heart's rhythmic contractions and relaxations are regulated by a complex electrical conduction system.

Cardiovascular agents are a class of medications that are used to treat various conditions related to the cardiovascular system, which includes the heart and blood vessels. These agents can be further divided into several subcategories based on their specific mechanisms of action and therapeutic effects. Here are some examples:

1. Antiarrhythmics: These drugs are used to treat abnormal heart rhythms or arrhythmias. They work by stabilizing the electrical activity of the heart and preventing irregular impulses from spreading through the heart muscle.
2. Antihypertensives: These medications are used to lower high blood pressure, also known as hypertension. There are several classes of antihypertensive drugs, including diuretics, beta-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors.
3. Anticoagulants: These drugs are used to prevent blood clots from forming or growing larger. They work by interfering with the coagulation cascade, which is a series of chemical reactions that lead to the formation of a blood clot.
4. Antiplatelet agents: These medications are used to prevent platelets in the blood from sticking together and forming clots. They work by inhibiting the aggregation of platelets, which are small cells in the blood that help form clots.
5. Lipid-lowering agents: These drugs are used to lower cholesterol and other fats in the blood. They work by reducing the production or absorption of cholesterol in the body or increasing the removal of cholesterol from the bloodstream. Examples include statins, bile acid sequestrants, and PCSK9 inhibitors.
6. Vasodilators: These medications are used to widen blood vessels and improve blood flow. They work by relaxing the smooth muscle in the walls of blood vessels, causing them to dilate or widen. Examples include nitrates, calcium channel blockers, and ACE inhibitors.
7. Inotropes: These drugs are used to increase the force of heart contractions. They work by increasing the sensitivity of heart muscle cells to calcium ions, which are necessary for muscle contraction.

These are just a few examples of cardiovascular medications that are used to treat various conditions related to the heart and blood vessels. It is important to note that these medications can have side effects and should be taken under the guidance of a healthcare provider.

Collateral circulation refers to the alternate blood supply routes that bypass an obstructed or narrowed vessel and reconnect with the main vascular system. These collateral vessels can develop over time as a result of the body's natural adaptation to chronic ischemia (reduced blood flow) caused by various conditions such as atherosclerosis, thromboembolism, or vasculitis.

The development of collateral circulation helps maintain adequate blood flow and oxygenation to affected tissues, minimizing the risk of tissue damage and necrosis. In some cases, well-developed collateral circulations can help compensate for significant blockages in major vessels, reducing symptoms and potentially preventing the need for invasive interventions like revascularization procedures. However, the extent and effectiveness of collateral circulation vary from person to person and depend on factors such as age, overall health status, and the presence of comorbidities.

A Severity of Illness Index is a measurement tool used in healthcare to assess the severity of a patient's condition and the risk of mortality or other adverse outcomes. These indices typically take into account various physiological and clinical variables, such as vital signs, laboratory values, and co-morbidities, to generate a score that reflects the patient's overall illness severity.

Examples of Severity of Illness Indices include the Acute Physiology and Chronic Health Evaluation (APACHE) system, the Simplified Acute Physiology Score (SAPS), and the Mortality Probability Model (MPM). These indices are often used in critical care settings to guide clinical decision-making, inform prognosis, and compare outcomes across different patient populations.

It is important to note that while these indices can provide valuable information about a patient's condition, they should not be used as the sole basis for clinical decision-making. Rather, they should be considered in conjunction with other factors, such as the patient's overall clinical presentation, treatment preferences, and goals of care.

The myocardium is the middle layer of the heart wall, composed of specialized cardiac muscle cells that are responsible for pumping blood throughout the body. It forms the thickest part of the heart wall and is divided into two sections: the left ventricle, which pumps oxygenated blood to the rest of the body, and the right ventricle, which pumps deoxygenated blood to the lungs.

The myocardium contains several types of cells, including cardiac muscle fibers, connective tissue, nerves, and blood vessels. The muscle fibers are arranged in a highly organized pattern that allows them to contract in a coordinated manner, generating the force necessary to pump blood through the heart and circulatory system.

Damage to the myocardium can occur due to various factors such as ischemia (reduced blood flow), infection, inflammation, or genetic disorders. This damage can lead to several cardiac conditions, including heart failure, arrhythmias, and cardiomyopathy.

Lateral sinus thrombosis, also known as sigmoid sinus thrombosis, is a medical condition characterized by the formation of a blood clot (thrombus) in the lateral or sigmoid sinus, which are venous structures located in the skull that help drain blood from the brain.

The lateral sinuses are situated near the mastoid process of the temporal bone and can become thrombosed due to various reasons such as infection (often associated with ear or mastoid infections), trauma, tumors, or other underlying medical conditions that increase the risk of blood clot formation.

Symptoms of lateral sinus thrombosis may include headache, fever, neck stiffness, altered mental status, and signs of increased intracranial pressure such as papilledema (swelling of the optic nerve disc). Diagnosis is typically made with the help of imaging studies like CT or MRI scans, and treatment often involves anticoagulation therapy to prevent clot expansion and potential complications. In some cases, surgical intervention may be necessary to remove the clot or manage any underlying conditions.

Platelet activation is the process by which platelets (also known as thrombocytes) become biologically active and change from their inactive discoid shape to a spherical shape with pseudopodia, resulting in the release of chemical mediators that are involved in hemostasis and thrombosis. This process is initiated by various stimuli such as exposure to subendothelial collagen, von Willebrand factor, or thrombin during vascular injury, leading to platelet aggregation and the formation of a platelet plug to stop bleeding. Platelet activation also plays a role in inflammation, immune response, and wound healing.

Chest pain is a discomfort or pain that you feel in the chest area. The pain can be sharp, dull, burning, crushing, heaviness, or tightness. It may be accompanied by other symptoms such as shortness of breath, sweating, nausea, dizziness, or pain that radiates to the arm, neck, jaw, or back.

Chest pain can have many possible causes, including heart-related conditions such as angina or a heart attack, lung conditions such as pneumonia or pleurisy, gastrointestinal problems such as acid reflux or gastritis, musculoskeletal issues such as costochondritis or muscle strain, and anxiety or panic attacks.

It is important to seek immediate medical attention if you experience chest pain that is severe, persistent, or accompanied by other concerning symptoms, as it may be a sign of a serious medical condition. A healthcare professional can evaluate your symptoms, perform tests, and provide appropriate treatment.

Prothrombin is a protein present in blood plasma, and it's also known as coagulation factor II. It plays a crucial role in the coagulation cascade, which is a complex series of reactions that leads to the formation of a blood clot.

When an injury occurs, the coagulation cascade is initiated to prevent excessive blood loss. Prothrombin is converted into its active form, thrombin, by another factor called factor Xa in the presence of calcium ions, phospholipids, and factor Va. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a stable clot.

Prothrombin levels can be measured through a blood test, which is often used to diagnose or monitor conditions related to bleeding or coagulation disorders, such as liver disease or vitamin K deficiency.

Vascular patency is a term used in medicine to describe the state of a blood vessel (such as an artery or vein) being open, unobstructed, and allowing for the normal flow of blood. It is an important concept in the treatment and management of various cardiovascular conditions, such as peripheral artery disease, coronary artery disease, and deep vein thrombosis.

Maintaining vascular patency can help prevent serious complications like tissue damage, organ dysfunction, or even death. This may involve medical interventions such as administering blood-thinning medications to prevent clots, performing procedures to remove blockages, or using devices like stents to keep vessels open. Regular monitoring of vascular patency is also crucial for evaluating the effectiveness of treatments and adjusting care plans accordingly.

... refers to the formation and presence of thrombi in the coronary arteries of the heart. Note that the heart ... Coronary sinus thrombosis as a severe complication after procedures. The coronary sinus is the venous counterpart to the ... Inflammation may play a causal role in coronary artery disease and subsequent myocardial infarction due to coronary thrombosis ... Coronary thrombosis is defined as the formation of a blood clot inside a blood vessel of the heart. This blood clot may then ...
This is a list of notable people who have died from coronary thrombosis, in chronological order. 1882: Charles Darwin (12 ... Deaths from coronary thrombosis, Lists of deaths from disease). ...
Coronary Thrombosis Fatal to Former 'Playboy' Who Shot Stanford White in 1906". The New York Times. February 22, 1947. ... Harry K. Thaw, 76, former multimillionaire playboy, died in his home here tonight of coronary thrombosis. "Died". Time magazine ... of coronary thrombosis; in Miami Beach. Eccentric girl-chaser Thaw put three bullets in White at a Manhattan roof garden for ... His family physician said that the attack of coronary ... "Benjamin Thaw Too Ill to be Told of His Brother's Crime". The New ...
Coronary Thrombosis among Women. Am J M Sc. 1938; 196: 815-818 Ingham, D.W. and F.A. Willius. Congenital Transposition of the ... Coronary Thrombosis Among Persons Less Than Forty Years of Age; a Study of Thirty Cases. Minnesota Medicine, St. Paul. 1939;33: ... Life Expectancy in Coronary Thrombosis. JAMA. 1936;106(22):1890-1894. Digitalis: Its Rational Use. Med. Clin. North Am. 1937;21 ... Bodily Build and Heredity in Coronary Thrombosis. Ann Intern Med. 1937;10(8):1181-1186 Willius, F.A. and T.J. Dry. Results From ...
... was the direct cause of coronary thrombosis; in fact the closest relationship between coronary deaths and any single dietary ... Yudkin, John (27 July 1957). "Diet and Coronary Thrombosis". The Lancet. 270 (6987): 155-162. doi:10.1016/s0140-6736(57)90614-1 ... the alarming increase in many countries during the first half of the twentieth century in the incidence of coronary thrombosis ... was to summarise the evidence that the consumption of sugar was leading to a greatly increased incidence of coronary thrombosis ...
He has suffered a coronary thrombosis. After a short time of rest, he returns to preaching, and accepts an appointment as ...
Cause of death was coronary thrombosis. His remains were sent to Ottawa for burial. He was interred in the Jewish Cemetery on ...
He proposed that thrombosis in the coronary artery leads to the symptoms and abnormalities of heart attacks and that this was ... Siegel R (May 1958). "The man who discovered coronary thrombosis; James Brain Herrick, 1861-1954". The Journal of the Medical ... Herrick JB (1918). "Concerning thrombosis of the coronary arteries". Transactions of the Association of American Physicians. 33 ... Herrick JB (October 1983). "Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. By ...
The cause of death was coronary thrombosis. His remains were returned to Pennsylvania. Following funeral services on February ...
... , a farm boy who built one of the largest rubber businesses in the world, died of a coronary thrombosis as ... In 1938, Firestone died of coronary thrombosis. Firestone, Henry Ford, and Thomas Edison were generally considered the three ...
McIntire died in 1963 of coronary thrombosis. "West Virginia Mountaineers football coaching records". Archived from the ...
He died of coronary thrombosis in 1949. Frost, Terry (1988). Bradford City A Complete Record 1903-1988. Breedon Books Sport. ... Deaths from coronary thrombosis, People from New Cumnock, People from Cambuslang, All stub articles, Scottish football forward ...
The cause of death was Coronary thrombosis. Narragansett Park's Old Colony Stakes was renamed the James H. Connors Memorial ...
He died of coronary thrombosis in 1940. William Few was a member of The Order of the Red Friars, a Duke University secret ...
Brown died of a coronary thrombosis in 1959. Brown was admitted to the Illinois bar in 1908. He joined the legal department of ...
McLester died from coronary thrombosis in Birmingham, Alabama. A portrait of McLester was unveiled in January, 2018 in the main ...
"Mechanisms of Coronary Thrombosis in Cigarette Smoke Exposure". Arteriosclerosis, Thrombosis, and Vascular Biology. 33 (7): ... of Acute coronary syndrome including unstable angina and myocardial infarction and the mechanisms of Coronary Thrombosis and ... "Angioscopic Evaluation of Coronary-Artery Thrombi in Acute Coronary Syndromes". New England Journal of Medicine. 326 (5): 287- ... John A. Ambrose is an American physician who is an expert in coronary artery disease. He is one of the pioneers in acute ...
His sudden death was caused by coronary thrombosis. As a resident at Johns Hopkins Hospital in Baltimore, Bloodgood was aware ...
He had a previous condition of coronary thrombosis. Even if suicide had been suspected, the LA County Coroner's Office would ... his death certificate actually states arteriosclerosis general and coronary sclerosis as the cause of death. ...
He was born and educated in Berlin, Germany; he died in Northampton, Massachusetts, from coronary thrombosis. He was influenced ... Koffka was forced to alter his lifestyle after developing a heart condition called Coronary thrombosis. However, his condition ...
The cause of death was recorded as coronary thrombosis. Hill was buried at Hollybrook Cemetery, near his birthplace in ... Deaths from coronary thrombosis, English comedy musicians, English male comedians, English male film actors, English male ...
Smith died of coronary thrombosis on 11 September 1940. He was buried in the Jewish section of Fawkner Cemetery with full ... Deaths from coronary thrombosis, Egyptian Jews, Jewish military personnel, Manchester Regiment soldiers, People from Alexandria ...
He died on February 13, 1937, from coronary thrombosis. William Suddards Franklin Nelle Franklin Joseph Franklin Thomas Z. ...
Fujitani died of coronary thrombosis on February 11, 1965. Notable women of Hawaii. Peterson, Barbara Bennett, 1942-. Honolulu ...
The officially reported cause of death was coronary thrombosis. The National Economic Association (NEA) awards the "Samuel Z. ...
In February 1955, he became ill with coronary thrombosis. His health worsened in October, and he died on October 12, 1955, at ...
Richards died in Salt Lake City of coronary thrombosis. He was buried at Salt Lake City Cemetery. After Richards's death, ...
On April 28, 1948, in Dayton, Ohio, Moseley became ill; later dying on June 6, 1948, to coronary thrombosis. His will dedicated ... Deaths from coronary thrombosis, 20th-century American botanists, 19th-century American botanists, American science writers, ...
September 24, 1955: President Eisenhower suffered a coronary thrombosis. November 5, 1955: Racial segregation was forbidden on ...
The department's physician attributed his death to Coronary thrombosis. He was 63 years old. "Francis X. Cotter Appointed Fire ...
Coronary thrombosis refers to the formation and presence of thrombi in the coronary arteries of the heart. Note that the heart ... Coronary sinus thrombosis as a severe complication after procedures. The coronary sinus is the venous counterpart to the ... Inflammation may play a causal role in coronary artery disease and subsequent myocardial infarction due to coronary thrombosis ... Coronary thrombosis is defined as the formation of a blood clot inside a blood vessel of the heart. This blood clot may then ...
Acute Platelet Thrombosis Formation in Stenosed Coronary Arteries Involves Serotonin S2 Platelet Receptors M I.M. Noble; M I.M ... M I.M. Noble, S Torr, J D Foltss; Acute Platelet Thrombosis Formation in Stenosed Coronary Arteries Involves Serotonin S2 ...
It occurs when a blood clot forms in one of the coronary arteries responsible for supplying blood to the heart muscle. This can ... Atherosclerosis is the most common cause of coronary ... Coronary thrombosis is a severe medical condition that can have ... Is a coronary thrombosis the same as a heart attack?. Is coronary artery thrombosis a heart attack? Not that they are not the ... What is a Coronary Thrombosis, and How Can it Affect You?. Coronary thrombosis, a heart attack or myocardial infarction, is a ...
... coronary thrombosis. 2. A coronary thrombosis, the doctor had called it. 3. Here is the coronary thrombosis at higher ... 4. This is coronary thrombosis, one of the complications of atheros ... More similar words: thrombosis, thrombolysis, coronary, coronary bypass, coronary artery, coronary care unit, coronary artery ... Similar words: thrombosis, thrombolysis, coronary, coronary bypass, coronary artery, coronary care unit, coronary artery ...
Sportsmen Coronary yoga in daily life thrombosis middle Rate. Fast.hit Support,div style=overflow:hidden;height:1px;,,a href ... Sportsmen Coronary yoga in daily life thrombosis middle Rate. The west functions end up somewhat more health-conscious nowadays ... One very much reduced the possibility of choosing any specific disorder linked on your coronary heart or perhaps coronary ... Sportsmen Coronary yoga in daily life thrombosis middle Rate ... coronary heart method. The work out there shall be arranged by ...
Coronary AngiographyStentsMyocardial InfractionPercutaneous Coronary InterventionBifurcationCoronary Artery FenestrationOptical ... Side Branch late thrombosis after left main coronary artery crossover stenting: a case report. ...
Coronary thrombosis. Its mechanism and possible prevention by linolenic acid. Ann Intern Med 1965;63: 167-84. ... Main outcome measure: Incidence of acute myocardial infarction or coronary death.. Results: During follow up 734 coronary ... Dietary intake of marine n-3 fatty acids, fish intake and the risk of coronary disease among men. N Engl J Med 1995;332: 977-82 ... Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States BMJ 1996; 313 :84 doi: ...
Thrombosis (coronary or pulmonary) * Trauma The "3 and 3 rule" of Desbiens [5] is of more practical use, because it allows easy ... Transient coronary occlusion usually does not cause PEA, unless hypotension or other arrhythmias are involved. ...
President Eisenhower suffers coronary thrombosis in Denver During his first term as President of the United States, Dwight D. ...
Angioplasty, Balloon, Coronary* * Coronary Angiography * Coronary Circulation * Coronary Thrombosis / epidemiology * Creatine ... The endpoints extracted were post-procedure residual stent thrombosis (ST) segment elevation and ST segment resolutions (STRes ... undergoing primary percutaneous coronary intervention (PCI) have yielded mixed results. Therefore, we performed a meta-analysis ... of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary ...
About treatment of acute coronary syndrome - acute treatment, the risk of recurrent events after initial ACS and assessing ... Coronary heart disease events are significantly more likely to be fatal in patients with a history of MI than in those without ... Latest In Thrombosis * Thrombosis Digest * 2022 * ESC 2022 Congress Highlights * International Society on Thrombosis and ... Latest in Thrombosis * Thrombosis Digest * 2022 * ESC 2022 Congress Highlights * International Society on Thrombosis and ...
Table 4 : Major Bleeding Events1 in Treatment of Acute Deep Vein Thrombosis With or Without Pulmonary Embolism. Indication. ... Table 3 : Efficacy of Once Daily INNOHEP® (tinzaparin) in the Treatment of Acute Deep Vein Thrombosis. Indication. Dosing ... Table 5 : Adverse Events Occurring in ≥ 1% in Treatment of Acute Deep Vein Thrombosis With or Without Pulmonary Embolism ... Table 8 : INNOHEP® (tinzaparin) Weight-based Dosing for Treatment of Deep Vein Thrombosis With or Without Symptomatic Pulmonary ...
... report a case in which DES-induced severe coronary vasospasm was clinically suspected as a cause of subacute stent thrombosis ( ... To our knowledge, the present case is the first report describing in-stent thrombosis secondary to stent-edge spasm. This case ... We performed a spasm provocation test to evaluate the coronary vasomotor response; it revealed severe stent-edge spasm in the ... He was diagnosed with effort angina by coronary angiography and underwent DES implantation in the mid-left ascending artery ( ...
Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. ... Although plaque rupture is the most common cause of coronary thrombosis, acute coronary syndromes may occur in the absence of ... Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks. Circulation ... Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999 Sep. 82(3):269-72. [ ...
Autopsy studies report acute thrombosis of coronary arteries in 80% of fatal cases. Risk factors most often associated with ... There was no evidence of coronary artery thrombosis. Examination of the brain showed diffuse cerebral edema, and cerebellar ... and right coronary arteritis. Microscopic examination of the heart showed inflammatory infiltrates of the right coronary artery ... The term "atypical Kawasaki disease" describes patients who do not have 4 of the 5 criteria but who have evidence of coronary ...
Coronary Stent Thrombosis- Predictors and Prevention. Ullrich H, Münzel T, Gori T. Ullrich H, et al. Among authors: gori t. ... Coronary Vasculitis. Gori T. Gori T. Biomedicines. 2021 May 31;9(6):622. doi: 10.3390/biomedicines9060622. Biomedicines. 2021. ... Coronary In-Stent Restenosis: Predictors and Treatment. Ullrich H, Olschewski M, Münzel T, Gori T. Ullrich H, et al. Among ... Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I ...
Shah PK [1997]. Plaque disruption and coronary thrombosis: new insight into pathogenesis and prevention. Clin Cardiol 20( ... Fuster V, Badimon JJ, Badimon JH [1992]. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J ... The risk of coronary heart disease due to smoking is reduced by half after 1 year of not smoking and then declines gradually ... Coronary Artery Disease (CAD) and the Pathophysiology of Myocardial Infarction. In the United States, atherosclerotic CAD is ...
Prevention and Management of Stent Thrombosis after Complex Coronary Stenting in Patients with Risk of Gastrointestinal ... Percutaneous Coronary Intervention: Procedures, Medical Uses and Adverse Effects. $45.00. - $98.00. Select options ...
Coronary Artery (Heart) Disease / Angina (24 profiles). *Coronary Thrombosis / Occlusion (23 profiles) ...
Electric Shock-Induced Coronary Artery Thrombosis and Dissection. Ann Thorac Surg. 2019 Feb. 107 (2):e105-e106. [QxMD MEDLINE ...
Aspirin may reduce coronary thrombosis at the expense of excess bleeding; clonidine may reduce hypertensive swings only to be ... trial of about 10 000 noncardiac-surgery candidates at risk for coronary complications. Aspirin given preoperatively and for 30 ...
... coronary thrombosis; aneurysm.. These benefit(s) will not duplicate any other benefits payable under the policy or any coverage ... coronary thrombosis; aneurysm.. These benefit(s) will not duplicate any other benefits payable under the policy or any coverage ... coronary thrombosis; aneurysm.. These benefit(s) will not duplicate any other benefits payable under the policy or any coverage ... coronary thrombosis; aneurysm.. These benefit(s) will not duplicate any other benefits payable under the policy or any coverage ...
Vascular disorders: thrombosis/embolism (coronary artery, pulmonary, cerebral, deep vein).. Hepatobiliary disorders: ... Ever had blood clots in your arms, legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis) ... Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1)] ● Have cerebrovascular ... Have coronary artery disease [see Warnings and Precautions (5.1)] ● Have thrombogenic valvular or thrombogenic rhythm diseases ...
His wife found him dead from coronary thrombosis (heart failure). Characteristically, Coolidges last will was brief and to the ...
Coronary thrombosis is a hell of a drug.. Thank you.. Reply. * grnmtnyeti ...
On September 23, 1955, he had a kind of heart attack called a coronary thrombosis. He remained hospitalized until November 11. ...
0.025) and greater predisposition to coronary thrombosis (odds ratio, 11.4; P. = 0.04). The extent of this polymorphism of the ... 0.008), and more calcifications of the coronary arteries (. P. = 0.01) than men who had fewer repeats. They also had a higher ... within the regulatory region of the gene on both alleles had a significantly greater number of severely narrowed coronary ...
Risk of thrombosis during coronary angioplasty with low osmolality contrast media. Am J Cardiol 1991; 68 (10) 1020-1024 ... 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/ ... Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105 (19 ...

No FAQ available that match "coronary thrombosis"

No images available that match "coronary thrombosis"